Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101386 | 0.89 | HRH3 (0.55) | HRH3TIPARPKDM4EALDH1A1LTA4H | |
| SCHEMBL30101340 | 0.89 | HRH3 (0.69) | HRH3TIPARPKDM4ETDP1TSHR | |
| SCHEMBL30101416 | 0.86 | HRH3 (0.53) | HRH3TIPARPKDM4ETSHRPOLB | |
| SCHEMBL30101529 | 0.81 | TIPARP (0.55) | HRH3TIPARPKDM4EALDH1A1SIGMAR1 | |
| SCHEMBL383947 | 0.80 | HRH3 (0.61) | HRH3KDM4EALDH1A1SIGMAR1CD274 | |
| SCHEMBL10256201 | 0.79 | HRH3 (0.46) | HRH3 | |
| SCHEMBL21744253 | 0.78 | HRH3 (0.56) | HRH3TIPARPKDM4ECD274TSHR | |
| SCHEMBL30101429 | 0.76 | HRH3 (0.46) | HRH3TIPARPALDH1A1SIGMAR1 | |
| SCHEMBL14641573 | 0.76 | KDM4E (0.48) | HRH3KDM4ELTA4HCD274 | |
| SCHEMBL11806412 | 0.76 | HRH3 (0.66) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | HRH3 1405/4885TIPARP 152/4885KDM4E 929/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | HRH3 1405/4885TIPARP 152/4885KDM4E 929/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | HRH3 1405/4885TIPARP 152/4885KDM4E 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.